RGEDF Stock Chart & Stats
$43.76
>-$0.01(-0.01%)
At close: 4:00 PM EDT
$43.76
>-$0.01(-0.01%)
Day’s Range― - ―
52-Week Range$27.00 - $45.28
Previous CloseN/A
Volume54.00
Average Volume (3M)436.00
Market Cap
$7.33B
Enterprise Value$1.94T
Total Cash (Recent Filing)$136.62B
Total Debt (Recent Filing)$21.74B
Price to Earnings (P/E)10.4
Beta0.66
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.26%
Share Statistics
EPS (TTM)1306.92
Shares Outstanding186,374,860
10 Day Avg. Volume265
30 Day Avg. Volume436
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap264.94
Enterprise Value/Revenue2.27
Enterprise Value/Gross Profit3.33
Enterprise Value/Ebitda5.12
Forecast
1Y Price Target
$45.03Price Target Upside2.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chemical Works of Gedeon Richter News
RGEDF FAQ
What was Chemical Works of Gedeon Richter Plc’s price range in the past 12 months?
Chemical Works of Gedeon Richter Plc lowest stock price was $27.00 and its highest was $45.28 in the past 12 months.
What is Chemical Works of Gedeon Richter Plc’s market cap?
Chemical Works of Gedeon Richter Plc’s market cap is $7.33B.
When is Chemical Works of Gedeon Richter Plc’s upcoming earnings report date?
Chemical Works of Gedeon Richter Plc’s upcoming earnings report date is Nov 10, 2026 which is in 11 days.
How were Chemical Works of Gedeon Richter Plc’s earnings last quarter?
Chemical Works of Gedeon Richter Plc released its earnings results on Aug 07, 2026. The company reported $1.732 earnings per share for the quarter.
Is Chemical Works of Gedeon Richter Plc overvalued?
According to Wall Street analysts Chemical Works of Gedeon Richter Plc’s price is currently Undervalued.
Does Chemical Works of Gedeon Richter Plc pay dividends?
Chemical Works of Gedeon Richter Plc pays a Annually dividend of $2.153 which represents an annual dividend yield of 5.26%. See more information on Chemical Works of Gedeon Richter Plc dividends here
What is Chemical Works of Gedeon Richter Plc’s EPS estimate?
Chemical Works of Gedeon Richter Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chemical Works of Gedeon Richter Plc have?
Chemical Works of Gedeon Richter Plc has 186,374,860 shares outstanding.
What happened to Chemical Works of Gedeon Richter Plc’s price movement after its last earnings report?
Chemical Works of Gedeon Richter Plc reported an EPS of $1.732 in its last earnings report. Following the earnings report the stock price went up 4.585%.
Which hedge fund is a major shareholder of Chemical Works of Gedeon Richter Plc?
Currently, no hedge funds are holding shares in RGEDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemical Works of Gedeon Richter Plc
Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. The firm focuses on central nervous system, women's healthcare, cardiovascular, and OTC products. It operates through the following segments: Neuropsychiatry (CNS), General Medicines (GM), Women’s Healthcare (WHC), Biotechnology (BIO), and Pharma Other. The CNS segment focuses on building a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry. The GM segment includes a traditional and generic portfolio in various therapeutic areas in the Central and Eastern European regions. The WHC segment provides pharmaceutical products for European women. The BIO segment is involved in its biotechnology platform to develop and manufacture biosimilar drugs for global markets. The Pharma Other segment relates to the remaining wholesale and retail business of the Group and all other activities. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.
RGEDF Company Deck
RGEDF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong underlying operational progress: solid constant-currency revenue growth (8.7%), a significant 21% rise in Clean EBIT on a constant-currency basis, robust biotech and CNS performance, record free cash flow, and measurable cost/ESG benefits from API consolidation. However, reported results were meaningfully impacted by FX losses (notably >HUF 32bn in Q2), a weaker General Medicines performance affected by timing and market factors, one-off impairments in Biotech, and restructuring costs. On balance, the operational wins, upgraded Clean EBIT guidance, cash generation and pipeline progress outweigh the transitory negatives driven largely by FX and one-off items, supporting a constructive outlook.View all RGEDF earnings summariesRGEDF Stock 12 Month Forecast
Average Price Target
$45.03
▲(2.91% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Teva
―
Perrigo Company
―
AstraZeneca
―
Pfizer
―
GlaxoSmithKline
―
Ownership Overview
―
Insiders
15.92% Mutual Funds
0.22% Other Institutional Investors
76.12% Public Companies and
Individual Investors